These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36572783)
1. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [ Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783 [TBL] [Abstract][Full Text] [Related]
2. Mass balance, metabolic disposition, and pharmacokinetics of [ Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, mass balance, and metabolism of [ Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H Cancer Chemother Pharmacol; 2024 Nov; 94(5):647-657. PubMed ID: 38507062 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects. Darwish M; Nunez R; Youakim JM; Robertson P Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Mass Balance, and Biotransformation of [ Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans. Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448 [TBL] [Abstract][Full Text] [Related]
7. Absorption, metabolism, and excretion of [ Yu J; Zhang H; Zhang Y; Zhan Y; Ma S; Hu T; Zhang N; Lou Y; Bao H; Xu Z; Zhong D; Miao L; Diao X Xenobiotica; 2022 Mar; 52(3):254-264. PubMed ID: 35373704 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Mass Balance and Metabolism of [ Yuan JJ; Bian YC; Ma S; Chen W; Zhang FY; Zhang H; Miao LY Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):723-731. PubMed ID: 37833493 [TBL] [Abstract][Full Text] [Related]
9. Excretion balance and pharmacokinetics following a single oral dose of [ Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109 [TBL] [Abstract][Full Text] [Related]
10. Absorption, metabolism, excretion, and safety of [ Zhou C; Xie L; Liu W; Zhang L; Zhou S; Wang L; Chen J; Li H; Zhao Y; Zhu B; Ding S; Zhang C; Shao F Ann Transl Med; 2021 May; 9(10):867. PubMed ID: 34164501 [TBL] [Abstract][Full Text] [Related]
11. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers. Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419 [TBL] [Abstract][Full Text] [Related]
12. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [ Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836 [TBL] [Abstract][Full Text] [Related]
13. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans. Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, absorption, metabolism, and excretion of [ Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648 [TBL] [Abstract][Full Text] [Related]
15. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633 [TBL] [Abstract][Full Text] [Related]
18. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [ Zhou S; Shao F; Xu Z; Wang L; Jin K; Xie L; Chen J; Liu Y; Zhang H; Ou N Cancer Chemother Pharmacol; 2017 Sep; 80(3):563-573. PubMed ID: 28730290 [TBL] [Abstract][Full Text] [Related]
19. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans. Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583 [TBL] [Abstract][Full Text] [Related]